Background: Tumor necrosis factor-␣ (TNF-␣) is a pro-inflammatory cytokine and may act as an endogenous tumor promoter. Single nucleotide polymorphisms (SNPs) of the TNF-␣ gene promoter region have been found to be associated with certain cancers. We conducted a case-control study to evaluate the association between these SNPs and nasopharyngeal carcinoma (NPC). Methods: We used polymerase chain reaction followed by restriction fragment length polymorphism analysis to determine the −308 TNF-␣ promoter genotypes of 89 NPC patients and 360 healthy controls. In 23 NPC patients and 50 controls, we determined the sequence from −1065 to −101 nucleotides of the TNF-␣ gene promoter region to detect SNPs. Results: In comparison with the controls, the NPC patients had higher proportions of men and carriage of IgA antibodies against the capsid antigen of Epstein-Barr virus, but had a similar carrier rate of the −308A allele (odds ratio [OR], 1.2; 95% confidence interval [CI], 0.7-2.0). The carriage of the −308A allele was not associated with the occurrence of NPC in comparison with −308G homozygosity. We also found no significant differences in the distributions of allelic variants of the −1031, −863, −857, and −806 loci of the TNF-␣ promoter region, but observed a lower carrier rate of the novel −806T allele in the NPC patients (OR, 0.3; 95% CI, 0.0-2.9). Conclusion: Allelic variants of the TNF-␣ promoter gene may not be used as biomarkers of susceptibility to NPC. The role of the −806T allele needs to be studied further. [J Chin Med Assoc 2006;69(8):351-357] 
Introduction
Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in Southeast Asia, including Taiwan, and has special geographic and ethnic distributions, with particularly high rates among southeastern Chinese and other individuals of Chinese descent. In addition to the Epstein-Barr virus (EBV), epidemiologic studies have suggested that environmental and host factors play important roles in the development of NPC. Cigarette smoking and Cantonese salted fish were shown to be associated with this disease, 1, 2 and in addition to environmental factors, familial clustering of NPC has long been documented in Chinese and other populations. The contribution of genetic factors to the carcinogenesis of NPC was supported by the finding that firstdegree relatives of NPC patients had a greater risk of NPC. 2 Furthermore, specific genotypes among certain genetic polymorphisms were found to be associated
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Single Nucleotide Polymorphisms of the Promoter Region of the Tumor Necrosis Factor-␣ Gene and Nasopharyngeal Carcinoma with susceptibility to NPC. [3] [4] [5] [6] [7] Genetic polymorphisms associated with susceptibility to NPC are being studied with great interest, especially single nucleotide polymorphisms (SNPs).
Recent studies have shown that human leukocyte antigen (HLA)-A and B alleles are associated with susceptibility to NPC, and suggested that other candidate genes might lie within or near HLA. 6, 7 Notably, the tumor necrosis factor-␣ (TNF-␣) gene occurs near the genomic segment between HLA-class I and II genes. TNF-␣ is a pro-inflammatory cytokine and may play a role in inflammatory pathways that increase tumorigenesis. 8 TNF-␣ has been found in high concentrations in patients with cancer, 9, 10 and some reports have suggested that it might act as an endogenous tumor promoter in vivo. 11, 12 In addition, data from the TNF-␣ receptor type 1 knockout mouse model have provided evidence of the essential role of TNF-␣ in carcinogenesis. 13 Several SNPs in the TNF-␣ promoter region, including those located at −1031, −863, −857, −575, −376, −308, −244, −238, +70, and +71 nucleotides relative to the start site of transcription, have been identified, 14 and some of them are associated with susceptibility to cancer. [15] [16] [17] [18] The expression of TNF-␣ can be regulated at the transcriptional level, and the differences in TNF-␣ production may be determined at the genetic level. Differential transcriptional activity and in vitro TNF-␣ production were found in patients carrying variants of SNPs at positions −1031, −863, −857, −308, and −238 in the TNF-␣ promoter region. [19] [20] [21] [22] Among these allelic variants, the −308 G/A allele has been extensively studied in terms of its effects on TNF-␣ gene regulation. The less common −308A allele was found to be associated with high baseline and induced expressions, 19, 20 and positive associations were found between the −308A allele and susceptibility to malignant tumors. 15, 16, 18 Other variants of TNF-␣ promoter SNPs are also related to high TNF-␣ production. 22 To evaluate the associations between these SNPs (with a focus on the variants of the −308 allele) and susceptibility to NPC, we conducted a case-control study in Taiwan.
Methods
Study population
Between January 2000 and December 2004, we recruited 89 consecutive patients with pathologically confirmed primary NPC from the oncology ward at a teaching hospital in Tainan, Taiwan. The extent of involvement was evaluated by physical examination, serologic markers of EBV, and imaging studies, including conventional X-rays, sonography, whole-body bone scan, computerized tomography scan, and magnetic resonance imaging. Clinical staging was based on the 1997 American Joint Committee on Cancer staging system. 23 An indirect immunofluorescence assay was used to test for IgA and IgG antibodies against the EBV capsid antigen (anti-EBV IgA and anti-EBV IgG). A titer less than 1:40 was considered to be negative for anti-EBV IgA, and a titer less than 1:640 was considered to be negative for anti-EBV IgG.
A total of 360 controls were recruited from participants in a health check-up program. None of the controls had a history of cancer or were found to have cancer during the health check-up. The controls were recruited during the study period consecutively, without matching to the patients. All participants were Taiwanese. Peripheral blood samples were taken from patients and controls, and blood specimens, including white blood cells and serum, were frozen at −70ºC until analysis. Informed consent was obtained from each participant included in this study, and the study protocol conformed to ethical guidelines as reflected by the approval of the institution's research committee.
Determination of SNPs of the TNF-a promoter region
From the peripheral blood leukocytes of each participant, we extracted genomic DNA using a DNA isolation kit (MBI Fermentas Ltd, Vinius, Lithuania), following the manufacturer's instructions. The −308 TNF-␣ promoter gene variants were determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis. A 117-base pair fragment of the TNF-␣ promoter region spanning −238 to −308 sites was generated by using 5Ј-AGG CAA TAG GTT TTG AGG GCC AT 3Ј and 5Ј-ACA CTC CCC ATC CTC CCT GCT C 3Ј as the primers. The thermocycling conditions were as follows: 95ºC for 5 minutes; 95ºC for 15 seconds, 60ºC for 30 seconds, and 72ºC for 30 seconds for 35 cycles, and then 72ºC for 7 minutes. Restriction enzyme of Nco1 (Boehringer Mannheim, Mannheim, Germany) digestion with the PCR product was carried out overnight and then analyzed on a 3% agarose gel. DNA products were visualized by ethidium bromide staining. An example of the gel electrophoresis of different genotypes is shown in Figure 1 . The detailed method is described in our previous report. 18 Among the study participants, 23 NPC patients and 50 controls were randomly chosen to determine other SNPs of the TNF-␣ promoter region. PCR was performed using primers to amplify the sequences between −1065 and −101 nucleotides (NCBI accession no. M16441) relative to the TNF-␣ transcription start site, using the sense primer −1084: 5Ј-GAT GGA CTC ACC AGG TGA G 3Ј and the antisense primer −81: 5Ј-TCC TTG GTG GAG AAA CCC AT 3Ј. The conditions of amplification were as follows: 95ºC for 5 minutes, 94ºC for 20 seconds, 57ºC for 20 seconds, and 72ºC for 60 seconds for 35 cycles, followed by 72ºC for 10 minutes. PCR products were purified using a Qiagen extraction kit. The fragments were then directly sequenced using the ABI Prism 377 DNA sequencer (PE Applied BioSystems, Foster City, CA, USA).
Statistical analysis
The differences in the distributions of genotypes and −308A allele carriage among the different groups of participants, defined by gender, age, and serologic markers of EBV, were evaluated by the 2 test or Fisher's exact test. In addition, we calculated odds ratios (ORs) for NPC associated with −308A allele carriage for different groups defined by gender, age, and serologic markers of EBV. The distributions of the other variants of the TNF-␣ promoter gene between patients and controls were also evaluated by the 2 test or Fisher's exact test. All statistical analyses were performed using an SAS package (SAS Institute, Cary, NC, USA), with the 2-tailed significance level set at 0.05.
Results
−308 TNF-a promoter gene polymorphism
The 89 NPC patients had a median age of 50 years (range, 30-79 years) at diagnosis, and 67 (75%) were men. The 360 controls had a median age of 53 years (range, 22-75 years), and 216 (60%) were men. In comparison with the controls, the NPC patients were younger and included a higher proportion of men.
On the basis of TNM staging, 6 (7%) patients were stage I, 25 (28%) stage II, 31 (35%) stage III, and 27 (30%) stage IV. Among patients and controls, the −308G/G homozygote was the predominant genotype at position −308 of the TNF-␣ promoter gene (patients 78%, controls 80%), while the −308A/A homozygote was uncommon (only 2 in the controls), but the distribution of the −308 genotype was not significantly different between the patients and controls. In comparison with the controls, patients had a higher proportion of positive anti-EBV IgA tests (86% vs. 6%, p < 0.001). Nonetheless, the positive rate for anti-EBV IgG was similar between the NPC patients and controls. Among patients and controls, distributions of the −308 genotypes and −308A allele carriage did not differ significantly in the subgroups defined by age, gender, anti-EBV IgA, or anti-EBV IgG ( Table 1 ). The carriage of the −308A allele (in both homozygous and heterozygous participants) was not associated with an increased risk for NPC (OR, 1.2; 95% confidence interval [CI], 0.7-2.0) in comparison with −308G homozygosity (Table 2) . Likewise, when patients and controls were stratified according to gender, age, and anti-EBV IgA, −308A allele carriage was not associated with increased ORs of developing NPC across all strata (p > 0.05 for all tests) ( Table 2 ).
Variants of SNPs in the TNF-␣ promoter gene
The sequence of the TNF-␣ promoter region was identified in 23 NPC patients and 50 controls. The NPC patients had a median age of 51 years (range, 30-74 years) at diagnosis, and 19 (83%) were men. The controls had a median age of 55 years (range, 32-75 years), and 37 (74%) were men. Among the 73 TNF-␣ promoter regions sequenced, we detected a new SNP at position −806 with less common T allele (Figure 2 region, but did not find −575, −376, −244, or −238 allelic variants. The −806T allele carrier rate was much lower among NPC patients (OR, 0.3; 95% CI, 0.0-2.9), but the difference was not statistically significant. In fact, no significant differences in these SNPs within the TNF-␣ promoter region were observed between the patients and controls in our study (Table 3) . 
Discussion
Taiwan is a hyperendemic area for NPC. While some cases may be attributable to environmental factors, such as smoking, EBV infection, and Cantonese salted foods, host susceptibility may also play an important role. A study in Taiwan showed that first-degree relatives of NPC patients had a relative risk of 19.2 for developing NPC. 2 More and more genetic polymorphisms have been found to be associated with NPC, including cytochrome P450 2E1, glutathione S-transferase M1, and DNA repair enzymes XRCC1 and hOGG1. [3] [4] [5] NPC has been found to be associated with HLA genes, particularly HLA-A*0207 and -B*4601 alleles, 7 and therefore it is suggested that other candidate genes might lie within or near HLA. Since nearly all NPC tumors are EBV-positive, it is postulated that individuals who inherit HLA alleles with a different ability to present EBV antigens to the immune system might be at different risk for developing NPC. The TNF-␣ gene is located in the major histocompatibility complex III gene region of chromosome 6, between the HLA-B and HLA-DR genes.
6,7 TNF-␣ is a pro-inflammatory cytokine, and evidence implicates the role of TNF-␣ in inflammatory pathways that increase tumorigenesis. 8 The production of TNF-␣ could be influenced by TNF-␣ promoter gene polymorphisms, and therefore TNF-␣ promoter polymorphisms may play a role in the pathogenesis of NPC. In the current study, we found that the frequency of the −308A allele of the TNF-␣ promoter gene is similar in the NPC patients compared to the controls, which indicates that the −308A allele of the TNF-␣ promoter gene is not a candidate biomarker for susceptibility to NPC. This observation is in agreement with 2 previous studies, 24, 25 and when we combined these 2 studies with the current study, we did not observe a significant difference in −308G/A distribution between a total of 277 NPC patients and 770 controls. In the previous 2 reports, however, no analyses of the distributions of −308 genotypes and allele carriage among different groups of participants, defined by gender, age, and serologic markers of EBV, were done. Studies on some other types of cancer, including breast carcinoma, hepatocellular carcinoma, and prostate carcinoma, have found associations with −308A allele carriage. 15, 16, 18 However, no association was observed in gastric cancer, uterine cervical cancer, and some hematologic malignancies. 17, 26 These findings may reflect the differing carcinogeneses of different types of cancer or of different populations.
Recently, at least 10 SNPs in the TNF-␣ promoter gene have been identified, and some of these SNPs may affect TNF-␣ promoter activity relative to high TNF-␣ production, 21, 22 although the actual biologic effect of these polymorphisms in vivo has not been clearly demonstrated. In the current study, we found a new SNP located at the −806 locus relative to the TNF-␣ transcription site. The −806 locus was reported by another research team at our institution with an allele frequency of 1% among 524 dyspeptic patients. 27 We conducted a search of the literature for this allele on MEDLINE but failed to locate any other article. The frequency of this allele was 12% among the normal controls in our study and was significantly higher than the 1% cut-off for defining SNP (p < 0.01), indicating that it is very likely to be a novel SNP. We found that the carriage of the −806T allele was associated with a decreased OR of 0.3 in developing NPC, but the result did not achieve statistical significance. The sample size of our study might limit the statistical power to determine whether the carriage plays a protective role in the development of NPC. Further assessments of −806T allele frequencies in other ethnic populations and the biologic functions of this SNP are warranted.
TNF-␣ promoter SNPs were reported to be associated with the susceptibility to, or the severity of some diseases such as psoriasis, adult periodontitis, human immunodeficiency virus type 1 viremia, and juvenile rheumatoid arthritis. 21, [28] [29] [30] Some variants have even been found to be associated with susceptibility to certain malignant tumors. 17, 31, 32 Nonetheless, we observed no association between any of these SNPs and NPC. Whereas our previous study found that the allele frequency of −308A was lower in Chinese than in Caucasians; 18 differences in the allele frequencies of −1031C, −863A, and −857T between the 2 groups need to be investigated further. Baena et al 14 documented the ethnic-specific patterns of TNF-␣ promoter SNPs, which can be used as markers of human ancestry. 14 We conducted a search of PubMed using combinations of the key words "TNF-␣" and "polymorphism" and identified 4 reports with data on these allele frequencies among healthy Chinese populations [33] [34] [35] [36] (Table 4 ). The weighted average of carriage rates was 36% for allelic variants of −1031C, 32% for −863A, and 29% for −857T. No significant differences were found among these SNPs in our NPC patients and pooled reference Chinese controls, which indicated that our controls were representative of the general Chinese population in terms of the allele frequencies. Therefore, the selection of controls in our study did not affect the outcomes.
In conclusion, our study found no association between the TNF-␣ promoter SNPs and NPC. This indicates that these variants of the TNF-␣ promoter may not be used as biomarkers to identify individuals who are more susceptible to NPC. However, the role of the novel −806T allele in the regulation of TNF-␣ production and its association with diseases need to be investigated further. 
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